Biosci Rep:干扰素诱导蛋白p202促进小鼠骨髓基质细胞的成骨

2018-06-23 MedSci MedSci原创

在本研究中,研究人员探讨了干扰素诱导蛋白p202在小鼠骨髓基质细胞(BMSCs)成骨细胞分化中的作用。 结果显示,在BMSC成骨过程中,p202的mRNA和蛋白质水平均先升高后降低。这种蛋白质的细胞内分布在分化过程中也发生了变化。p202敲低抑制 而p202过表达增强 BMSCs的成骨细胞分化。通过评估成骨标志物的表达,茜素红S染色和碱性磷酸酶活性的测定来鉴定此结果。进一步的研究显示p202干扰R

在本研究中,研究人员探讨了干扰素诱导蛋白p202在小鼠骨髓基质细胞(BMSCs)成骨细胞分化中的作用。

结果显示,在BMSC成骨过程中,p202的mRNA和蛋白质水平均先升高后降低。这种蛋白质的细胞内分布在分化过程中也发生了变化。p202敲低抑制 而p202过表达增强 BMSCs的成骨细胞分化。通过评估成骨标志物的表达,茜素红S染色和碱性磷酸酶活性的测定来鉴定此结果。进一步的研究显示p202干扰Runx2/Id复合物的形成并释放Runx2以诱导分化过程。

综上所述,该研究结果表明,p202在BMSCs成骨中发挥了积极的作用。

原始出处:

Zhang L, Wang C, Zhang X, Li H. The interferon-inducible protein p202 promotes osteogenesis in mouse bone marrow stromal cells. Biosci Rep. 2018 May 31. pii: BSR20171618. doi: 10.1042/BSR20171618. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786017, encodeId=7f241e8601704, content=<a href='/topic/show?id=5c8d136044a' target=_blank style='color:#2F92EE;'>#p202#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13604, encryptionId=5c8d136044a, topicName=p202)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Aug 02 22:43:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918146, encodeId=ca9d191814662, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 23 06:43:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757102, encodeId=bc0b1e57102ea, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sat Apr 13 07:43:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351752, encodeId=b50d1351e529c, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 25 12:43:00 CST 2018, time=2018-06-25, status=1, ipAttribution=)]
    2018-08-02 skhzy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786017, encodeId=7f241e8601704, content=<a href='/topic/show?id=5c8d136044a' target=_blank style='color:#2F92EE;'>#p202#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13604, encryptionId=5c8d136044a, topicName=p202)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Aug 02 22:43:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918146, encodeId=ca9d191814662, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 23 06:43:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757102, encodeId=bc0b1e57102ea, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sat Apr 13 07:43:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351752, encodeId=b50d1351e529c, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 25 12:43:00 CST 2018, time=2018-06-25, status=1, ipAttribution=)]
    2018-09-23 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786017, encodeId=7f241e8601704, content=<a href='/topic/show?id=5c8d136044a' target=_blank style='color:#2F92EE;'>#p202#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13604, encryptionId=5c8d136044a, topicName=p202)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Aug 02 22:43:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918146, encodeId=ca9d191814662, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 23 06:43:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757102, encodeId=bc0b1e57102ea, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sat Apr 13 07:43:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351752, encodeId=b50d1351e529c, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 25 12:43:00 CST 2018, time=2018-06-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786017, encodeId=7f241e8601704, content=<a href='/topic/show?id=5c8d136044a' target=_blank style='color:#2F92EE;'>#p202#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13604, encryptionId=5c8d136044a, topicName=p202)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Aug 02 22:43:00 CST 2018, time=2018-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918146, encodeId=ca9d191814662, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Sep 23 06:43:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757102, encodeId=bc0b1e57102ea, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Sat Apr 13 07:43:00 CST 2019, time=2019-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351752, encodeId=b50d1351e529c, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Jun 25 12:43:00 CST 2018, time=2018-06-25, status=1, ipAttribution=)]
    2018-06-25 zhaojie88

相关资讯

FDA拒绝了Celgene旗下的Ozanimod用于多发性硬化症

Celgene周二(2018年2月27日)宣布,它已收到FDA拒绝关于该公司在治疗复发型多发性硬化症患者中使用Ozanimod的市场推广申请的信函。Celgene解释说,经过初步审查,FDA认为Celgene提交的非临床和临床药理学部分不足以进行全面审查。Celgene首席医疗官Jay Backstrom评论说:“我们将继续与FDA合作,尽快解决所有未解决的问题,并将这种重要药物带给患者。”

Aliment Pharmacol Therap:亚洲慢性基因型1丙型肝炎患者适合跟干扰素说再见吗?

二十多年来,IFN一直是慢性丙型肝炎(HCV)抗病毒疗法的基础药物。然而,含IFN疗法与一系列不良事件相关,探索无IFN疗法非常有必要。目前无干扰素(IFN)的DAA治疗HCV GT1感染的亚洲患者的可靠真实世界证据仍然有限。2018年3月,发表在《Aliment Pharmacol Ther》的一项Meta分析对此进行了调查。

Circ J:HCV抗病毒治疗减少了心力衰竭等心血管事件的发生

抗病毒治疗CHC,有助于减少住院患者发生心力衰竭、血管事件和心血管死亡事件的发生

J Periodontol: 慢性和侵袭性牙周炎患者牙龈组织中干扰素-λ的表达

一些研究已经证明慢性和侵袭性牙周炎患者牙周袋中存在疱疹病毒。最近发现,干扰素λ(IFN-λ)具有抗病毒特性并且由疱疹病毒诱导。本研究旨在定量分析慢性和侵袭性牙周炎患者牙龈组织中IFN-λs(IFN-λ1,IFN-λ2,IFN-λ3)的mRNA表达。

J Viral Hepat:IFNAR2 -rs1051393, rs12233338可能是中国人群HBV感染的预测标志物

IFNAR2 -rs1051393, rs12233338可能是中国人群HBV感染的预测标志物

Dig Liver Dis:真实世界中,OBT/PTV-r+RBV治疗HCV基因4型(进展期肝纤维化)患者,疗效良好,可获得较高SVR

本研究表明,在真实世界中,OBT/PTV-r+RBV治疗可使HCV基因4型(进展期肝纤维化)患者,疗效良好